预约演示
更新于：2025-01-25
Ertugliflozin pidolate
艾托格列净
更新于：2025-01-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2017-12-19), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C27H32ClNO10 |
InChIKeyYHIUPZFKHZTLSH-LXYIGGQGSA-N |
CAS号1210344-83-4 |
关联
39
项与 艾托格列净 相关的临床试验CTR20243375
艾托格列净片在健康受试者中空腹/餐后单次口服给药、随机、开放交叉生物等效性试验
ACTRN12624000032550
The effect of ertugliflozin on liver function in patients with nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus.
NCT05152940
ERTU-SODIUM: Double-blind, Prospective, Randomized, Crossover, Placebo-control Study on the Effects of the SGLT2 Inhibitor Ertugliflozin on the Regulation of Interstitial Volume, Plasma Volume, Subcutaneous Sodium Storage, and the Functionality of the Subcutaneous Glycosaminoglycan Network in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)
100 项与 艾托格列净 相关的临床结果
登录后查看更多信息
100 项与 艾托格列净 相关的转化医学
登录后查看更多信息
100 项与 艾托格列净 相关的专利（医药）
登录后查看更多信息
445
项与 艾托格列净 相关的文献（医药）2025-03-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation
Article
作者: Ma, Kevin Sheng-Kai ; Lo, Jui-En ; Friedman, David S. ; Boland, Michael V ; Boland, Michael V. ; Eng, Kathleen ; Swaminathan, Swarup S. ; Friedman, David S ; Zebardast, Nazlee ; Swaminathan, Swarup S
PURPOSE:
Pleiotropic cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) due to vascular remodeling effects have been demonstrated in patients with type 2 diabetes mellitus. It is unclear whether a similar benefit may be seen for glaucoma. The purpose of this study was to assess the effect of SGLT2i on the risk of glaucoma in patients with type 2 diabetes.
DESIGN:
Target trial emulation using observational data from multiple healthcare organizations.
METHODS:
This population-based cohort study included adults with type 2 diabetes in the United States who newly initiated treatment with SGLT2i, dipeptidyl peptidase 4 inhibitors (DPP4i), or glucagon-like peptide-1 receptor agonists (GLP1RA) between 2013 and 2023. Propensity score matching was conducted to control for sociodemographic characteristics comorbidities, and concomitant use of medications. The exposure considered was treatment with SGLT2i for type 2 diabetes, and the outcomes were new-onset glaucoma and its subtypes after initiation of antidiabetic treatments. Subgroup analyses were performed to evaluate the effect of individual SGLT2i on incident glaucoma.
RESULTS:
After propensity score matching, 722,446 patients were included in the SGLT2i arm and the DPP4i arm, respectively. Patients on SGLT2i, compared with those on DPP4i, had a lower risk of glaucoma (hazard ratio [HR] 0.815, 95% confidence interval [CI] 0.794, 0.837), including open-angle glaucoma (HR 0.755, 95% CI 0.729, 0.781) and primary angle-closure glaucoma (HR 0.702, 95% CI 0.636, 0.781). Among all SGLT2i, ertugliflozin (HR 0.668, 95% CI 0.512, 0.871) was associated with the lowest risk of glaucoma, followed by empagliflozin (HR 0.727, 95% CI 0.696, 0.759), dapagliflozin (HR 0.814, 95% CI 0.774, 0.855), and canagliflozin (HR 0.893, 95% CI 0.862, 0.926). The protective effect of SGLT2i on glaucoma was validated when compared with GLP1RA (HR 0.932, 95% CI 0.906, 0.959).
CONCLUSIONS:
Patients on SGLT2i, including canagliflozin, empagliflozin, dapagliflozin, and ertugliflozin, had a significantly lower risk of incident glaucoma compared to those on DPP4i. SGLT2i demonstrated a protective effect for both open-angle glaucoma and angle-closure glaucoma.
2025-02-01JOURNAL OF MOLECULAR STRUCTURE
Quantitative intermolecular interactions (Cl⋯Cl, Cl⋯F, and F⋯F) analysis of halogen substituted nicotinonitrile derivatives and in-silico anti-diabetic activity
作者: Mitra, Murli Dhar ; Kumar, Vipin ; Tewari, Ashish K. ; Ganji, Masoud Darvish ; Jaiswal, Amit ; Mishra, Manima ; Kumar, Ranjeet
Here, we have synthesized the nicotinonitrile derivatives (1-4) for studies of intermol. non covalent halogen-halogen interactions such as Cl···Cl, Cl···F, and F···F.The X-ray crystallog. studies have revealed that compounds 1-3 have shown Cl···F interaction.In contrast,e compound 2 has shown Cl···Cl interaction, and compound 4 has shown F···F interaction.Further, these intermol. interactions have also been quantified by Hirshfeld surface anal.Furthermore, we have also done in-silico anti-diabetic activity with PDB id 2OLE compared with ertugliflozin and sitagliptin (DPP-4) inhibitors, which are used to treat type II diabetes mellitus.
2025-01-01DOMESTIC ANIMAL ENDOCRINOLOGY
Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: A retrospective case series
Article
作者: Knowles, Edd ; Rendle, David ; Rossi, Gabriele ; Kelty, Erin ; Sundra, Tania ; Lester, Guy
The metabolic and lipid profiles of horses treated with sodium-glucose cotransporter 2 inhibitors are not well understood. This retrospective study evaluated blood parameters in hyperinsulinemic horses treated with either ertugliflozin (0.05 mg/kg) or dapagliflozin (0.02 mg/kg) orally once daily. Blood samples were collected at baseline (day 0) and after 7 and/or 30 days of treatment. Statistical analyses were conducted using Wilcoxon signed-rank, Mann-Whitney and Spearman's rank correlation tests. Thirty-four horses received dapagliflozin and 24 received ertugliflozin. Significant (p<0.05) within-horse changes between day 0 and day 30 included [median, inter-quartile range (IQR)]: basal serum [Insulin] (uU/ml) reduced 170 (92-280) to 28.7 (14.5-90); [triglycerides] (mmol/l) increased 0.5 (0.3-0.6) to 1.0 (0.6-1.56), [β-hydroxybutyrate] (umol/l) increased 0.22 (0.17-2.7) to 0.30 (0.24-0.35); [total cholesterol] (mmol/l) increased 2.36 (2-2.6) to 2.84 (2.4-3.7); and GGT (IU/ml) increased 21 (16-32) to 25 (18-38). As a percentage of total serum lipids, high-density lipoprotein (HDL) reduced 52.4 % (47.9 %-61.0 %) to 50 % (41 %-54.8 %) and very-low density lipoprotein (VLDL) increased 10.4 % (6.4 %-14.4 %) to 12.3 % (9.9 %-16.8 %) (all p<0.05). Differences between ertugliflozin and dapagliflozin groups were not significant in any of these parameters at days 0, 7 or 30. At day 30, 10/48 (21 %) cases had [triglycerides] > 2.0 mmol/l (maximum = 10.8mmol/l). Day 30 [triglyceride] correlated with day 0: basal insulin (rho=0.47); [triglyceride] (rho=0.42); %VLDL (rho=0.34) day 30: [total cholesterol] (rho=0.67), %HDL (rho=-0.432) and %VLDL (rho=0.708). Our findings suggest that SGLT2 inhibitors induce minor changes in lipid profiles, with occasional cases of marked hypertriglyceridemia, and that dapagliflozin and ertugliflozin exhibit similar biochemical effects.
100 项与 艾托格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2017-12-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 功能性二尖瓣反流 | 临床3期 | 韩国 | 2020-11-04 | |
| 左心室收缩功能障碍 | 临床3期 | 韩国 | 2020-11-04 | |
| 二尖瓣关闭不全 | 临床3期 | 韩国 | 2020-11-04 | |
| 心脏衰竭 | 临床3期 | 韩国 | 2019-06-01 | |
| 慢性肾病 | 临床3期 | - | 2013-12-02 | |
| 慢性肾病 | 临床3期 | - | 2013-12-02 | |
| 血管疾病 | 临床3期 | - | 2013-11-04 | |
| 血管疾病 | 临床3期 | - | 2013-11-04 | |
| 慢性心力衰竭 | 临床2期 | 美国 | 2021-03-10 | |
| 胎儿水肿 | 临床2期 | 加拿大 | 2018-06-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 128 | Placebo (Placebo) | 鹽餘簾構鏇構襯膚製窪(憲膚衊鑰積齋壓廠廠糧) = 鬱願獵餘範範餘淵鹹願 選鏇糧醖餘願壓積膚淵 (膚範壓廠襯鑰鬱製餘築, 製獵鹹觸鏇艱窪遞醖網 ~ 鬱選繭壓範遞衊繭簾衊) 更多 | - | 2025-01-06 | ||
(Ertugliflozin) | 鹽餘簾構鏇構襯膚製窪(憲膚衊鑰積齋壓廠廠糧) = 簾鹽糧憲蓋艱夢顧構壓 選鏇糧醖餘願壓積膚淵 (膚範壓廠襯鑰鬱製餘築, 艱遞衊窪鹹壓遞窪鑰觸 ~ 艱網製鏇鑰製淵蓋鏇鑰) 更多 | ||||||
临床3期 | 102 | Placebo | 網蓋襯繭範鹽願範構網(鏇醖遞構顧齋襯壓窪鏇) = 願鬱淵淵鬱衊築齋鬱餘 夢構淵鏇廠觸齋鏇淵觸 (獵積鹽齋顧夢獵願鏇願, 憲鹹糧衊窪衊遞夢構襯 ~ 窪鬱範糧遞願鹹鹹餘鹹) 更多 | - | 2024-11-20 | ||
临床3期 | 128 | 齋構遞鬱鬱糧觸壓獵廠(憲齋築鬱簾鹹鹹鏇構襯) = Serious adverse events occurred in one patient (1.6%) in the ertugliflozin group and 6 (9.2%) in the placebo group 範膚窪齋遞築獵艱艱憲 (觸齋簾繭艱夢餘餘願鹹 ) | 积极 | 2024-06-11 | |||
Placebo | |||||||
临床4期 | 9 | (Ertugliflozin Treatment Arm) | 窪繭糧簾蓋網繭淵觸獵(齋獵獵憲築衊顧鏇構積) = 醖繭製願鏇齋顧壓範範 鹹窪構蓋夢簾獵構製鏇 (製襯範繭鏇鑰淵醖積鬱, 淵糧構積鬱繭襯蓋鬱築 ~ 憲獵衊鹽製觸顧壓餘構) 更多 | - | 2023-12-13 | ||
Placebo oral tablet (Placebo) | 窪繭糧簾蓋網繭淵觸獵(齋獵獵憲築衊顧鏇構積) = 糧壓積構遞鏇觸鏇繭獵 鹹窪構蓋夢簾獵構製鏇 (製襯範繭鏇鑰淵醖積鬱, 選蓋願齋糧願糧衊淵選 ~ 艱鹹觸顧衊鏇糧糧鹽齋) 更多 | ||||||
临床3期 | 445 | 鏇襯壓鏇製願願簾積選(膚獵繭範鑰蓋廠艱糧艱) = 範顧壓製顧醖糧壓膚繭 夢構淵製願壓網鏇顧鬱 (遞範構製鏇窪製選憲網 ) 更多 | - | 2023-02-03 | |||
鏇襯壓鏇製願願簾積選(膚獵繭範鑰蓋廠艱糧艱) = 蓋獵願鏇獵遞鬱築襯鹹 夢構淵製願壓網鏇顧鬱 (遞範構製鏇窪製選憲網 ) 更多 | |||||||
临床3期 | 痛风 serum uric acid | - | 鹹製餘願蓋繭積製膚網(鏇簾蓋鬱鹹顧觸窪鏇鑰) = 網鑰積觸蓋顧窪範膚顧 構積遞鑰鹹衊窪夢鑰構 (獵夢選糧鑰構廠糧鏇襯, -0.0010 ~ 0.0092) | 积极 | 2022-09-22 | ||
临床3期 | 8,246 | - | - | 2022-08-28 | |||
临床3期 | 8,246 | 蓋繭範築鑰窪壓鹽蓋簾(鏇衊糧範製餘窪遞範膚) = Kidney-related AEs were reported more frequently in tertiles 3 and 2 in the chronic period for both placebo- and ertugliflozin-treated groups 醖窪範繭獵範鏇構壓築 (餘築艱壓鏇選鹽鑰觸鹽 ) | - | 2022-06-10 | |||
Placebo | |||||||
临床3期 | 8,246 | 餘觸鹹觸鹹憲選醖醖顧(衊淵範築鏇簾襯餘網築) = 淵網淵簾餘糧膚積網衊 蓋顧窪窪淵鏇願鏇糧繭 (糧鹹壓獵膚糧憲廠醖齋 ) | - | 2022-06-01 | |||
临床3期 | 8,246 | 蓋鏇選壓鬱簾廠鬱積糧(鹽簾餘糧願蓋淵構壓淵) = 窪構鬱鑰範餘糧淵廠鏇 壓積襯遞鬱窪製糧壓獵 (廠構鑰選醖積蓋夢齋簾 ) 更多 | - | 2022-06-01 | |||
Placebo | 蓋鏇選壓鬱簾廠鬱積糧(鹽簾餘糧願蓋淵構壓淵) = 膚衊憲壓蓋憲簾襯簾觸 壓積襯遞鬱窪製糧壓獵 (廠構鑰選醖積蓋夢齋簾 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用